Medtronic plc MDT SPX
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems and sensors, and InPen, a smart insulin pen. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Attractive dividend yield of 3.85%.
- Generates positive free cash flow.
CONS
- Earnings shrank at -2.6% CAGR over 5 years.
- Trading 28.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MDT Medtronic plc SPX | 73.81 | 20.62 | $94.76B | 3.85% | 8.07% | 9.39% | 1.91% | -2.56% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Apr 2015 | Jul 2015 | Oct 2015 | Jan 2016 | Apr 2016 | Jul 2016 | Oct 2016 | Jan 2017 | Apr 2017 | Jul 2017 | Oct 2017 | Jan 2018 | Apr 2018 | Jul 2018 | Oct 2018 | Jan 2019 | Apr 2019 | Jul 2019 | Oct 2019 | Jan 2020 | Apr 2020 | Jul 2020 | Oct 2020 | Jan 2021 | Jul 2021 | Oct 2021 | Jan 2022 | Jul 2022 | Oct 2022 | Jan 2023 | Jul 2023 | Oct 2023 | Jan 2024 | Jul 2024 | Oct 2024 | Jan 2025 | Apr 2025 | Jul 2025 | Oct 2025 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | 7.39B | 7.05B | 7.37B | 8.14B | 7.38B | 7.48B | 7.55B | 8.15B | 7.49B | 7.71B | 7.72B | 6.00B | 6.51B | 7.65B | 7.78B | 7.99B | 7.85B | 7.76B | 7.37B | 7.58B | 7.73B | 7.70B | 7.98B | 8.09B | 7.92B | 8.40B | 8.29B | 8.93B | 8.58B | 8.96B | 9.02B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.78B | 3.15B | 3.00B | 3.06B | 3.26B |
| Gross Profit | 4.37B | 4.82B | 4.88B | 4.79B | 5.20B | 4.91B | 5.02B | 5.01B | 5.48B | 5.04B | 4.93B | 5.17B | 5.75B | 5.18B | 5.28B | 5.28B | 5.66B | 5.13B | 5.31B | 5.32B | 3.73B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.51B | 5.78B | 5.58B | 5.90B | 5.76B |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.80B | 3.98B | 4.06B | 4.20B | 4.15B |
| Operating Income | - | 1.13B | 1.30B | 1.35B | - | 1.17B | 1.39B | 1.15B | - | 1.38B | 1.89B | 1.44B | - | 1.24B | 1.54B | 1.54B | - | 1.49B | 1.35B | 1.64B | - | 673.00M | 930.00M | 1.28B | 859.00M | 1.56B | 1.66B | 1.12B | 1.40B | 1.39B | 1.27B | 1.34B | 1.48B | 1.28B | 1.59B | 1.71B | 1.80B | 1.52B | 1.70B | 1.60B |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.40B | 2.27B | 2.23B | 2.52B | 2.33B |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 179.00M | 174.00M | 176.00M | 181.00M | 181.00M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.54B | 1.26B | 1.30B | 1.60B | 1.40B |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 237.00M | 199.00M | 255.00M | 215.00M | 254.00M |
| Net Income | -1.00M | 820.00M | 520.00M | 1.09B | 1.10B | 929.00M | 1.11B | 821.00M | 1.16B | 1.02B | 2.02B | -1.39B | 1.46B | 1.07B | 1.11B | 1.27B | 1.17B | 864.00M | 1.36B | 1.92B | 646.00M | 487.00M | 489.00M | 1.27B | 763.00M | 1.31B | 1.48B | 929.00M | 427.00M | 1.22B | 791.00M | 909.00M | 1.32B | 1.04B | 1.27B | 1.29B | 1.06B | 1.04B | 1.37B | 1.14B |
| Diluted EPS | 0.00 | 0.57 | 0.36 | 0.77 | 0.78 | 0.66 | 0.80 | 0.59 | 0.84 | 0.74 | 1.48 | -1.03 | 1.07 | 0.79 | 0.82 | 0.94 | 0.87 | 0.64 | 1.01 | 1.42 | 0.48 | 0.36 | 0.36 | 0.94 | 0.56 | 0.97 | 1.10 | 0.70 | 0.32 | 0.92 | 0.59 | 0.68 | 0.99 | 0.80 | 0.99 | 1.01 | 0.82 | 0.81 | 1.07 | 0.89 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Apr 2013 | Apr 2014 | Apr 2015 | Apr 2016 | Apr 2017 | Apr 2018 | Apr 2019 | Apr 2020 | Apr 2021 | Apr 2022 | Apr 2023 | Apr 2024 | Apr 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 29.71B | 29.95B | 30.56B | 28.91B | 30.12B | 31.69B | 31.23B | 32.36B | 33.54B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | 10.14B | 10.72B | 11.22B | 11.63B |
| Gross Profit | - | 12.67B | 13.95B | 19.69B | 20.42B | 20.90B | - | - | - | 21.54B | 20.51B | 21.15B | 21.91B |
| Operating Expenses | - | - | - | - | - | - | - | - | - | 15.63B | 14.68B | 15.63B | 15.37B |
| Operating Income | 4.40B | 3.81B | 3.77B | 5.36B | 5.38B | 6.64B | 6.27B | 4.79B | 4.48B | 5.91B | 5.83B | 5.52B | 6.54B |
| EBITDA | - | - | - | - | - | - | - | - | - | 8.78B | 8.70B | 8.20B | 9.22B |
| Interest Expense | - | - | - | - | - | - | - | - | - | 553.00M | 636.00M | 719.00M | 729.00M |
| Pretax Income | - | - | - | - | - | - | - | - | - | 5.52B | 5.36B | 4.84B | 5.63B |
| Tax Provision | - | - | - | - | - | - | - | - | - | 456.00M | 1.58B | 1.13B | 936.00M |
| Net Income | 3.47B | 3.06B | 2.67B | 3.54B | 4.03B | 3.10B | 4.63B | 4.79B | 3.61B | 5.04B | 3.76B | 3.68B | 4.66B |
| Diluted EPS | 3.37 | 3.02 | 2.41 | 2.48 | 2.89 | 2.27 | 3.41 | 3.54 | 2.66 | 3.73 | 2.82 | 2.76 | 3.61 |
Compounded Sales Growth
| 5 Years: | 1.91% |
| 1 Year: | 8.70% |
Compounded Profit Growth
| 5 Years: | -2.56% |
| 1 Year: | -11.80% |
Stock Price Performance
| 1 Year: | -8.22% |
| 6 Months: | -28.85% |
| 3 Months: | -23.80% |
| 1 Month: | -7.01% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Apr 2012 | Apr 2013 | Apr 2014 | Apr 2015 | Apr 2016 | Apr 2017 | Apr 2018 | Apr 2019 | Apr 2020 | Apr 2021 | Apr 2022 | Apr 2023 | Apr 2024 | Apr 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 37.94B | 106.69B | 99.64B | 99.86B | 91.39B | 89.69B | 90.69B | 93.08B | 90.98B | 90.95B | 89.98B | 91.68B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | 23.06B | 21.68B | 21.93B | 23.81B |
| Cash & Equivalents | 1.17B | 919.00M | 1.40B | 4.84B | 2.88B | 4.97B | 3.67B | 4.39B | 4.14B | 3.59B | 3.71B | 1.54B | 1.28B | 2.22B |
| Inventory | - | - | - | - | - | - | - | - | - | - | 4.62B | 5.29B | 5.22B | 5.48B |
| Receivables | - | - | - | - | - | - | - | - | - | - | 5.55B | 6.00B | 6.13B | 6.51B |
| Total Liabilities | - | - | 18.50B | 53.45B | 47.58B | 49.53B | 40.57B | 39.48B | 39.82B | 41.48B | 38.26B | 39.28B | 39.56B | 43.42B |
| Current Liabilities | - | - | 5.56B | 9.17B | 7.17B | 14.26B | 10.08B | 8.47B | 10.37B | 8.51B | 12.39B | 9.05B | 10.79B | 12.88B |
| Long Term Debt | - | - | - | 33.17B | 29.94B | 25.87B | 23.69B | 24.55B | 22.14B | - | 20.32B | 24.29B | 23.88B | 25.59B |
| Total Debt | - | - | - | - | - | - | - | - | - | - | 24.11B | 24.36B | 25.02B | 28.52B |
| Total Equity | 17.11B | 18.67B | 19.44B | 53.23B | 52.06B | 50.21B | 50.72B | 50.09B | 50.74B | 51.43B | 52.55B | 51.48B | 50.21B | 48.02B |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | 1.33B | 1.33B | 1.31B | 1.28B |
Cash Flows (Annual)
Figures in USD.
| Metric | Apr 2013 | Apr 2014 | Apr 2015 | Apr 2016 | Apr 2017 | Apr 2018 | Apr 2019 | Apr 2020 | Apr 2021 | Apr 2022 | Apr 2023 | Apr 2024 | Apr 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | 4.96B | 4.90B | 5.22B | 6.88B | 4.68B | 7.01B | 7.23B | 6.24B | 7.35B | 6.04B | 6.79B | 7.04B |
| Investing Cash Flow | - | -3.59B | -17.06B | 2.25B | -1.57B | 5.86B | -774.00M | -3.20B | -2.87B | -1.66B | -3.49B | -2.37B | -1.94B |
| Financing Cash Flow | - | -918.00M | 15.95B | -9.54B | -3.28B | -11.95B | -5.43B | -4.20B | -4.14B | -5.34B | -4.96B | -4.45B | -4.36B |
| Capital Expenditure | -457.00M | -396.00M | -571.00M | -1.05B | -1.25B | -1.07B | -1.13B | -1.21B | -1.35B | -1.37B | -1.46B | -1.59B | -1.86B |
| Free Cash Flow | - | 4.56B | 4.33B | 4.17B | 5.63B | 3.62B | 5.87B | 6.02B | 4.88B | 5.98B | 4.58B | 5.20B | 5.18B |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | 352.00M | -2.41B | -29.00M | 746.00M |
| Share Buybacks | 1.25B | 2.55B | 1.92B | 2.83B | 3.54B | 2.17B | 2.88B | 1.33B | 652.00M | 2.54B | 645.00M | 2.14B | 3.23B |
Ratios (Annual)
Figures in %.
| Metric | Apr 2013 | Apr 2014 | Apr 2015 | Apr 2016 | Apr 2017 | Apr 2018 | Apr 2019 | Apr 2020 | Apr 2021 | Apr 2022 | Apr 2023 | Apr 2024 | Apr 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | 68.7% | 69.8% | - | - | - | 68.0% | 65.7% | 65.3% | 65.3% |
| Operating Margin % | - | - | - | - | 18.1% | 22.2% | 20.5% | 16.6% | 14.9% | 18.6% | 18.7% | 17.1% | 19.5% |
| Net Margin % | - | - | - | - | 13.6% | 10.4% | 15.2% | 16.6% | 12.0% | 15.9% | 12.0% | 11.4% | 13.9% |
| ROE % | 18.6% | 15.8% | 5.0% | 6.8% | 8.0% | 6.1% | 9.2% | 9.4% | 7.0% | 9.6% | 7.3% | 7.3% | 9.7% |
| ROCE % | - | 11.8% | 3.9% | 5.8% | 6.3% | 8.2% | 7.7% | 6.0% | 5.3% | 7.5% | 7.1% | 7.0% | 8.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 8.82% | 113.18M | $8.35B |
| 2 | Vanguard Capital Management LLC | 6.49% | 83.33M | $6.15B |
| 3 | State Street Corporation | 4.81% | 61.74M | $4.56B |
| 4 | JPMORGAN CHASE & CO | 3.97% | 50.97M | $3.76B |
| 5 | Capital Research Global Investors | 3.27% | 41.93M | $3.09B |
| 6 | Vanguard Portfolio Management LLC | 2.61% | 33.45M | $2.47B |
| 7 | Geode Capital Management, LLC | 2.24% | 28.74M | $2.12B |
| 8 | Bank of America Corporation | 2.03% | 26.02M | $1.92B |
| 9 | Massachusetts Financial Services Co. | 1.67% | 21.44M | $1.58B |
| 10 | Morgan Stanley | 1.61% | 20.72M | $1.53B |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MDT